NeuroSigma Inc. spun out NSVascular Inc. to develop two stent lines using thin-film nitinol technology developed at the University of Calif.-Los Angeles under an exclusive licensing agreement.
Los Angeles-based NeuroSigma said its new subsidiary plans to develop one type of stent to treat brain aneurysms and another to treat peripheral artery disease.
